Wall Street expects a year-over-year increase in earnings on lower revenues when Nektar Therapeutics (NKTR) reports results for the quarter ended March 2025. While this widely-known consensus ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nektar Therapeutics before investing. In this article, we go over a few key ...